观察单纯介入微球栓塞治疗化疗无效的非小细胞肺癌患者的近、远期疗效及生存情况。

收集2011年8月至2015年9月鞍钢总医院介入治疗中心收治的经化疗后无效的Ⅲa~Ⅳa期非小细胞肺癌105例（介入栓塞组），予以支气管动脉经微导管超选择微球栓塞，3个月后复查，必要时行再次栓塞。选取同期我院化疗科Ⅲa~Ⅳa期非小细胞肺癌患者76例（化疗对照组），使用PE方案及MIC方案联合化疗。3~4周化疗1次，3、4个化疗周期为1个疗程，持续4~6个周期。两组均是每3个月进行1次复查、病情评估及疗效评价。

介入栓塞组的有效率（RR）为74.3%，高于化疗对照组的45.5%，差异有统计学意义（P=0.025），介入栓塞组的中位生存时间为14.5个月，长于化疗对照组的11个月，两组生存率差异有统计学意义（P=0.042）。

对于化疗不敏感的非小细胞肺癌患者，行单纯介入微球栓塞是一种安全、有效的姑息性治疗方法。

To study the short-term and long-term therapeutic effects and survival of interventional microsphere embolization in the treatment of non-small cell lung cancer (NSCLC) invalid after chemotherapy.

NSCLC patients (105 cases) who failed after chemotherapy during August 2011 to September 2015 in Angang General Hospital were as interventional embolization group (group A) , treated with embolization of bronchial artery using embosphere transcathter, re-examined after 3 months and re-embolized when necessary. NSCLC patients (76 cases) in our hospital during the same period were selected as chemotherapy control group (group B) , and treated with PE regimen and MIC regimen. The two groups were reviewed and evaluated every 3 months.

The effective rates of groups A and B were 74.3% and 45.5% (P=0.025) . The median survival time was 14.5 months and 11 months in groups A and B, respectively (P=0.042) .

There are statistical difference between two ways. It is effective and safe for NSCLC failed by chemotherapy using interventional microsphere bronchial artery embolization.